Confusion surrounding the treatment of cancer in the pediatric population can be very daunting especially if one is not a pediatric oncologist. Herein is described a pediatric case of mixed cell ovarian germ cell tumor that was complicated by Wernicke's encephalopathy which improved with standard treatment. This case report highlights the basic treatment plan of mixed cell ovarian germ cell tumor for the general pediatrician as sometimes the general pediatrician can be caught in the midst of a battle between specialists.
Introduction
Some confusion may be evident when deciding how to treat an adolescent with ovarian cancer, which is due in part to the rarity of the disease. Ovarian cancer becomes more prevalent with age. We present a case of a 13 year old female with mixed cell ovarian germ cell tumor that developed Wernicke's encephalopathy (WE) which improved with treatment.
Case Report
The patient is a 13 year old white female with no significant past medical history who presented to her pediatrician with decreased appetite, fatigue and weight loss. The patient's physical exam was significant for pallor, a palpable abdominal mass in the left hypochondrium which was firm, and nontender. The patient also had a 50 pound weight loss over the previous 5 weeks. A Computerized tomography (CT) scan showed an abdominal mass (Fig .1) .
The laboratory values on admission revealed a white blood cell count of 20.7 with differential of neutrophils 88%, bands 1%, lymphocytes 3%, monocytes 8%, hemoglobin 7.6, hematocrit 24.1, platelets 551, prothrombin time 16.5, internationalized ratio 1.41, partial thromboplastin time 38.3, sodium 136 mmol/L, potassium 3.8 mmol/L, chloride 101 mmol/L, bicarbonate 23 mmol/L, blood urea nitrogen 4 mg/dl, creatinine 0.4 mg/dl, calcium 8.5 mg/dl, total protein 7.1 g/dl, albumin 2.4 g/dl, AST 30 u/L, ALT 12 u/L, alkaline phosphatase 55 u/L.
Manuscript accepted for publication January 19, 2012 a Both pediatric oncology and gynecology (OB/GYN) were consulted on admission after which tumor markers were checked showing cancer antigen 125 (CA 125) of 754.5 u/ml, carcinoembryonic antigen (CEA) of 3.3 ng/ml, Beta human chorionic gonadotropin (Beta hCG) < 1 miU/ml, Lactate dehydrogenase (LDH) 381 u/L, and Alpha-fetoprotein (AFP) 95 ng/ml.
Shortly after admission the patient began complaining of dyspnea. A CT of the chest revealed pleural effusions (Fig.  2) . Thoracentesis was performed showing atypical cells consistent with immature teratoma, some large cells weakly positive for CD30 (possible embryonal carcinoma). The patient also developed acute kidney injury with an increase of serum creatinine of 0.9 mg/dl to 2 mg/dl. OB/GYN took the patient to surgery and performed a tumor resection with omentectomy and lymph node biopsy which the patient tolerated well. The pathology report revealed a 31 cm mixed germ cell tumor with focal high grade embryonal carcinoma, free floating nests of immature teratoma (Fig. 3) , and no lymph node or vascular involvement.
The day after surgery, the patient developed tingling in hands which rapidly progressed to weakness in all extremities. Workup for this complaint included Magnetic Resonance Imaging (MRI) of the brain and spinal cord which showed swelling of the mammillary bodies consistent with Wernickes Encephalopathy. Electromyography (EMG) revealed peripheral axonal neuropathy. A lumbar puncture (LP) was done with unremarkable findings (glucose 57 mg/ dl, protein 42 mg/dl, nucleated cells 0, RBCs 0). Paraneoplastic panel, which includes Anti-Neuronal Nuclear Antibodies (ANNA)-1, ANNA-2, ANNA-3, Purkinje Cell Cytoplasmic Antibodies (PCA)-1, PCA-2, , PCA-TR, Amphiphysin Ab, Collapsin response-mediator protein-5 immunoglobin (CRMP-5), Anit-glial/neuronal nuclear antibody (AGNA)-1 was negative. Other labs included Vitamin B12: 498 pg/ml, folate 2.5 ng/ml, thyroid stimulating hormone (TSH) 1.54 uiU/ml, antinuclear antibody (ANA) negative, Human Immunodeficiency Virus (HIV) negative, rapid plasma reagin (RPR) negative, Vitamin B6: 3.3 ug/L, iron:17 ug/dl, TIBC :153 ug/dl, transferrin saturation: 11%.
Due to MRI findings and the clinical picture, the patient was started on intravenous thiamine. Within a day the patient showed improvement in her clinical status. The patient's strength improved (from 0/5 to 2/5 all extremities) and the patient had return of sensation in her extremities. Electrocardiogram (EKG) was within normal limits and, echocardiography (ECHO) was obtained to evaluate for cardiomyopathy due to thiamine deficiency (wet beri beri) was unremarkable.
Repeat tumor markers were improved: CA-125 of 69 u/ml, AFP 9.0 ng/ml, and CEA 0.8 ng/ml. Chemotherapy regimen included Carboplatin, Etoposide and Bleomycin for 3 days followed by 7 days of granulocyte cell stimulating factor (G-CSF). The patient tolerated first round of chemotherapy well. The patient received a second round of chemotherapy. She tolerated the chemotherapy well and was able to be discharged home, 3 months after re-section the patient is still doing well, tumor markers show AFP 1.3 ng/ ml, CA 125: 14.5 u/ml, and CEA 0.7 ng/ml. The patient still remains somewhat weak with strength being 2/5 in the upper extremities.
Discussion
Germ cell tumors in children are rare. Some would estimate approximately 2.4/1,000,000 children will develop a germ cell tumor. They have the ability to be malignant or benign and do metastasize [1] . The usual sites of metastasis are the central nervous system, the lymphatic system, and the lungs [1].
The main histological classification of germ cell tumors in children is mature teratoma, immature teratoma, and malignant germ cell tumor. The types of malignant germ cell tumors are seminoma, dysgerminoma, yolk sac tumor, choriocarcinoma, embryonal carcinoma, and mixed germ cell tumors [2] .
A mixed germ cell tumor has at least 2 different types of tumor with germ cell elements that are mixed together. The different types of germ cell elements that can be present include yolk sac tumour, followed by immature teratoma, embryonal carcinoma, dysgerminoma and mature teratoma. The treatment of the mixed germ cell tumor is multidisciplinary. The primary treatment is surgical resection followed by chemotherapy usually platinum-based regimens [2] [3] [4] [5] [6] . Many years ago these tumors were sometimes treated primarily with methotrexate, dactinomycin, cyclophosphamide; however, this has fallen out of favor as many patients would progress on this therapy [3, 4] .
There appears to be several staging systems available. Most have similar elements for the staging but seem to subdivide the different stages. For the purposes of this paper the following staging system will be used. Stage I: Localized disease completely resected without microscopic disease [2] . Stage II: Microscopic residual disease, capsular invasion, or microscopic lymph node involvement [2] . Stage III: Gross residual disease, gross lymph node involvement (> 2 cm), or cytologic evidence of tumor cells in ascites [2] . Stage IV: Disseminated disease involving lungs, liver, brain, or bone [2] .
In this patient, the most difficult part was obtaining consensus between the specialists. The pediatric oncologist wanted resection prior to chemotherapy. The OB/GYN physicians wanted chemotherapy prior to resection. The national cancer institute has some general guidelines which should help clinicians in the future to help decide which type of treatment should be used for the germ cell tumors. Patients with stage I disease should undergo surgery (unilateral salpingo-oophorectomy) [5] . Most patients undergo post-op chemotherapy (except dysgerminoma and low-grade (grade I) immature teratoma). Observation for stage I is also reasonable. For stage II disease, the patient should undergo surgery (unilateral salpingo-oophorectomy) [5] followed by chemotherapy with BEP (cisplatin, etoposide, and bleomycin) and VAC (vincristine, dactinomycin, and cyclophosphamide ) as salvage therapy [2, [6] [7] [8] [9] [10] . A second look laparotomy is usually not helpful except in the instances of a sub-total resection, evidence of residual tumor via radiography, or teratomatous elements in the primary tumor [2, 8, 11] . Stage III disease, the patient should undergo surgery (abdominal hysterectomy and bilateral salpingo-oophorectomy is recommended, or unilateral salpingo-oophorectomy if preservation of fertility is desired) [5, 11] According to some authors, if the tumor is very large then three to four courses of chemotherapy may be required prior to debulking surgery [2, [6] [7] [8] 12] . Again second look surgery does not appear to be beneficial except in the same cases as stage II [2, 8, 12] . Stage IV disease, the patient should undergo surgery with abdominal hysterectomy and bilateral salpingo-oophorectomy [2] . Again if the tumor is large then consider chemotherapy first. The same rules apply as stage III in considering the second look surgery option [2, 7] .
Conclusion
In the end, the decision was made to have our patient undergo resection first followed by adjunctive chemotherapy. The patient developed wernicke's encephalopathy and neuropathy acutely post-op due to thiamin deficiency and stress, but the condition quickly reverted with therapy. The tumor markers decreased markedly after the resection and the chemotherapy. All stages of ovarian germ cell tumor require resection with most physicians opting for post-op adjuvant chemotherapy. In some instances, treatment with chemotherapy prior to resection is reasonable. More research is needed to help delineate the best course of action in the treatment of ovarian cancer.
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